Global Dialysis - FDA decides to not approve diet drug Orexigen's Contrave at the present time.

FDA decides to not approve diet drug Orexigen's Contrave at the present time.

NY Times: In a rare move, the agency told the drug maker, Orexigen Therapeutics, that to win approval it must first do a long-term study to demonstrate that the drug, called Contrave, does not raise the risk of heart attacks.

...